AACR Meeting II 2020 Participation

Presentations

Circulating Tumor DNA for Patient Stratification
A multi-gene prostate cancer liquid biopsy with > 92% accuracy in diagnosis and assessment of disease status
Authors: Kambiz Rahbar, Mark Kidd, Ignat Drozdov, Alexandra Kitz, Anna Malczewska, Pawel Rajwa, Christof Bernemann, Lisa Bodei, Irvin Modlin
Session: June 23; 10:05 AM

The Evolving Role of the Pathologist in Cancer Research
High-dimensional imaging technologies in pathology diagnosis and cancer research
Author: David L. Rimm
Abstract: 3
Session: June 23; 12:45 PM

Clinical Trial Design: Part 2: Clinical Trials Issues with Molecularly Targeted Agents
Incorporating translational research into clinical trials of targeted agents
Author: Katerina A. Politi
Session: June 23; 1:15 PM

Cancer Increases in Younger Populations: Where Are They Coming from?
Early-onset colorectal cancer
Author: Xavier Llor
Session: June 23; 1:45 PM

Dharma Master Jiantai Symposium in Biomarkers: High-Dimensional Imaging of Immune and Tumor Cells in Human FFPE Tissue
Understanding the immune composition of human lung cancer using multiparametric and spatially resolved tissue analysis
Author: Kurt Alex Schalper
Session: June 23; 4:00 PM

Cancer Immunity
3424 - IL-18 immunotherapy is efficacious against checkpoint-immunotherapy refractory tumors by promoting the maturation of highly proliferative, polyfunctional NK cells
Clinical Trial Design: Part 3: Clinical Development of IO Agents
Combination strategies with IO agents
Author: Roy S. Herbst
Session: June 24; 2:15 PM

Posters

Mechanisms of Sensitivity and Resistance to Targeted Therapy 3
Genomic, transcriptomic, and epigenetic profiling of triple-negative breast cancer cells after Navitoclax treatment
Authors: Michal Marczyk, Vignesh Gunasekharan, Jun Zhao, Rihao Qu, Xiaotong Li, Gauri A. Patwardhan, Vikram B. Wali, Abhishek K. Gupta, Manoj M. Pillai, Yuval Kluger, Christos Hatzis, B
Abstract: 6333
Poster: 16
Session: June 22; 9:00 AM

Immune Response to Therapies 1
VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer
Authors: Alicia Ding, Franz Villarroel-Espindola, Adam Ducler, Brian S. Henick, Shruti Desai, Nicole Gianino, Jon Zugazagoitia, David L. Rimm, Alain Robert, Francisco Cruzalegui, Pierre Ferré, Roy Herbst, Miguel Sanmamed, Lieping Chen, Kurt A. Schalper
Abstract: 5525
Poster: 15
Session: June 22; 9:00 AM

Novel Antitumor Agents 2
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma
Authors: Elena Bonazzoli, Stefania Bellone, Luca Zammataro, Barbara Gnutti, Adele Guglielmi, Silvia Pelligra, Paola Manara, Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, Alessandro D. Santin
Abstract: 5341
Poster: 30
Session: June 22; 9:00 AM

Immune Cells in the Tumor Microenvironment 4
Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients
Authors: Vesal Yaghoobi, Vasiliki Pelekanou, Tess O’Meara, Andrea Silber, Lajos Pusztai, David Rimm, Kim Blenman
Abstract: 4973
Poster: 8
Session: June 22; 9:00 AM
Mechanisms of Drug Action 1

Combination of the Aurora A inhibitor TAS-119 and adavosertib results in synergistic c-Jun-mediated cell death in head and neck and lung cancers
Authors: Jong Woo Lee, Cindy Yang, Barbara Burtness
Abstract: 604
Poster: 1
Session: June 22; 9:00 AM

Predictive Biomarkers for Treatment Efficacy 1

Diagnostic utility of the NETest in neuroendocrine transformed prostate cancer
Authors: Kambiz Rahbar, Mark Kidd, Ignat Drozdov, Alexandra Kitz, Anna Malczewska, Lisa Bodei, Pawel Rajwa, Christof Bernemann, Irvin Modlin
Abstract: 1999
Poster: 7
Session: June 22; 9:00 AM

Predictive Biomarkers for Treatment Efficacy 1

Biomarker discovery in immunotherapy-treated melanoma patients with imaging mass cytometry
Authors: Sandra Martinez-Morilla, Franz Villarroel-Espindola, Pok Fai Wong, Harriet Kluger, Maria Toki, Thazin New Aung, Vasiliki Pelekanou, Brian Bourke-Martin, David L. Rimm
Abstract: 2001
Poster: 9
Session: June 22; 9:00 AM

Predictive Biomarkers for Treatment Efficacy 1

Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLC
Authors: Yuting Liu, Jon Zugazagoitia, Kurt A. Schalper, Roy S. Herbst, David L. Rimm
Abstract: 2002
Poster: 10
Session: June 22; 9:00 AM

Adaptive Immunity to Tumors

IL-18 pathway agonism expands intratumoral PD1+ Tcfl+ stem-like CD8+ cells and their polyfunctional effector progeny to promote anti-tumor immunity
Authors: Ting Zhou, Orr-El Weizman, William Damsky, Meaghan McGeeary, Marcus W. Bosenberg, Aaron M. Ring
Abstract: 2156
Poster: 17
Session: June 22; 9:00 AM

Mechanisms of DNA Damaging Therapeutics

Exploiting inherent DNA damage repair defects in IDH1/2 mutated gliomas with the CNS penetrant PARP inhibitor, pamiparib
Authors: Christopher Hong, Amrita Sule, Jason Beckta, Ranjini Sundaram, Ranjit Bindra
Abstract: 1389
Poster: 25
Session: June 22; 9:00 AM
Circulating Markers 3

Combination of spatial protein data with bulk transcriptional profiling of the same cohort shows relationships between RNA and protein and facilitates combined predictive signatures
Authors: Ioannis A. Vathiotis, Jason Reeves, Maria Toki, Pok Fai Wong, Harriet Kluger, Thazin Nwe Aung, Konstantinos N. Syrigos, Sarah Warren, David L. Rimm
Abstract: 3095
Poster: 5
Session: June 22; 9:00 AM

Immune Checkpoints 1

Quantitative assessment of CD200 and CD200R expression in lung cancer
Authors: Ioannis A. Vathiotis, Tyler MacNeil, Jon Zugazagoitia, Sandra Martinez-Morilla, Fahad Ahmed, Konstantinos N. Syrigos, Aaron M. Gruver, Kyla Driscoll, David L. Rimm
Abstract: 937
Poster: 20
Session: June 22; 9:00 AM

Mechanisms of Resistance and Sensitivity to EGFR Targeting

Hypoxia induces EGFR inhibitor resistance in lung cancer cells by upregulation of fibroblast growth factor receptor 1 (FGFR1) via MAPK pathway
Authors: Yuhong Lu, Yanfeng Liu, Sebastian Oeck, Gary J. Zhang, Peter M. Glazer
Abstract: 1877
Poster: 21
Session: June 22; 9:00 AM

Preclinical Advances and Novel Cell Cycle Targets

Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer models
Authors: Zhigui Li, Jing Ji, Gloria S. Huang
Abstract: 4851
Poster: 13
Session: June 22; 9:00 AM

Innovative Assay Technologies

Novel seroprofiling assay reveals previously undescribed autoantibody responses in immunotherapy treated cancer patients
Authors: Connor E. Rosen, Yile Dai, Miguel F. Sanmamed, Aaron M. Ring
Abstract: 6292
Poster: 5
Session: June 22; 9:00 AM

New Imaging-based Approaches to Plan, Monitor, and Augment Cancer Treatment

Mapping the extracellular pH gradient of colorectal cancer after immuno-thermal ablation
Authors: Daniel Coman, Johannes M. Ludwig, Hyun S. Kim
Abstract: 2778
Poster: 10
Session: June 22; 9:00 AM

Obesity, Physical Activity, and Related Biomarkers
Do obese patients present with worse breast cancer?
Authors: Julian Huang, Anees Chagpar
Abstract: 3502
Poster: 21
Session: June 22; 9:00 AM

Signaling through Growth Factor Receptors, Kinases, and Phosphatases in Cancer
PPP6C regulation of ERK signaling in melanoma
Authors: Eunice Cho, Hua Jane Lou, Benjamin E. Turk
Abstract: 3754
Poster: 8
Session: June 22; 9:00 AM

Modulation of DNA Repair, New Nonclinical Models for Targets, and Other Targets
Characterization of ATRX loss combined with IDH1 R132H mutation in gliomas
Authors: Jennifer Garbarino, Ranjit Bindra, Ryan Jensen
Abstract: 4134
Poster: 11
Session: June 22; 9:00 AM

Model Organisms for Cancer Research
Role of aldehyde dehydrogenase 1B1 in colon carcinogenesis in a newly developed mouse model
Authors: Wan Ying Tan, David. J. Orlicky, Ying Chen, Yatrik M. Shah, David C. Thompson, Vasilis Vasililiou
Abstract: 6141
Poster: 25
Session: June 22; 9:00 AM

Phase I Clinical Trials
An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort
Authors: Patricia LoRusso, Javier García-Corbacho, Fadi S. Braiteh, Anthony Gonçalves, Francesco Ricci, Hiroji Iwata, Marta Capelán, Marie Paule Sablin, Aleix Prat, Molly Catherine Hardebeck, Marta Puig, Dennis Chin-Lun Huang, Mingchi Hsu, Douglas Yee
Abstract: CT165
Session: June 22; 9:00 AM

Late-Breaking Research: Clinical Research 2
Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis
Authors: Barbara Burtness, Danny Rischin, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto De Castro, Amanda Psysrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Joy Ge, Ramona Swaby, Burak Gumuscu, Kevin Harrington
Abstract: LB-258
Poster: 2
Session: June 22; 9:00 AM

Epigenetic Targets
**Prodigiosin inhibits the proliferation and migration of mcf-7 breast cancer cells through the demethylation of mir-200c gene**

Authors: Lingeng Lu, Peng LV, Ya Li, Hou Li, Xinyi Chen, Yong Zhu

Abstract: 1755
Poster: 14
Session: June 22; 9:00 AM

**Mathematical Modeling**

* A computational model for the PI3K/Akt/mTOR pathway predicts PTEN as a negative feedback loop

Authors: Kiran Vanaja Radha Mukherjee, Neal Rosen, Andre Levchenko

Abstract: 5506
Poster: 24
Session: June 22; 9:00 AM

**Genomics and Genetic Susceptibility**

* Genome-wide interaction scan identifies gene by smoking interaction at 2q21.3 for pancreatic cancer risk

Authors: Evelina Mocci, William Wheeler, Laufey T. Amundadottir, Donghui Li, Eric J. Jacobs, Gloria M. Petersen, Brian M. Wolpin, Harvey A. Risch, Peter Kraft, Nilanjan Chatterjee, Alison P. Klein, Rachael Z. Stolzenberg-Solomon

Abstract: 1213
Poster: 21
Session: June 22; 9:00 AM

**Gene and Vector-Based Therapy**

* Development of MAEGI as a new class of immune gene therapy for cancer treatment

Author: Sidi Chen

Abstract: 4070
Poster: 19
Session: June 22; 9:00 AM

**Phase I Clinical Trials**

* A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors

Authors: Patricia LoRusso, Ani Balmanoukian, Sam Klempner, D R. Camidge, Matthew Hellmann, Michael Gordon, Johanna Bendell, Lars Mueller, Rachel Sabado, Patrick Twomey, Leila Delamarre, Jack Huang, Mahesh Yadav, Jingbin Zhang, Patrick McDonald, Felicitas Müller, Evelyina Derhovanessian, Özlem Türeci, Ugur Sahin, Lillian Siu

Abstract: CT-169
Session: June 22; 9:00 AM

**Late-Breaking Research: Clinical Research 2**

* Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3)

Authors: Michael Cecchini, Manuel Modiano, Fadi Braiteh, Olivia S. Gardner, Houston N. Gilbert, Daniel DiRenzo, Lisa Seitz, Matt J. Walters, Fangfang Yin, Rachel Woloski, Melissa C. Paoloni, Ki Y. Chung

Abstract: LB-387
Poster: 11
Session: June 22; 9:00 AM